MXPA05005923A - Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma. - Google Patents

Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.

Info

Publication number
MXPA05005923A
MXPA05005923A MXPA05005923A MXPA05005923A MXPA05005923A MX PA05005923 A MXPA05005923 A MX PA05005923A MX PA05005923 A MXPA05005923 A MX PA05005923A MX PA05005923 A MXPA05005923 A MX PA05005923A MX PA05005923 A MXPA05005923 A MX PA05005923A
Authority
MX
Mexico
Prior art keywords
markers
identification
treatment
patients
proteasome inhibition
Prior art date
Application number
MXPA05005923A
Other languages
English (en)
Inventor
J Damokosh Andrew
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32507743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05005923(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MXPA05005923A publication Critical patent/MXPA05005923A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)

Abstract

La presente invencion se refiere a la identificacion de marcadores que pueden usarse para determinar si los pacientes con cancer responden o no responden clinicamente a un regimen terapeutico antes del tratamiento. En particular, la presente invencion se refiere al uso de ciertas combinaciones de marcadores, en donde la expresion de los marcadores se correlaciona con la respuesta o no respuesta a un regimen terapeutico que comprende la inhibicion de la proteasoma. Asi, al examinar los niveles de expresion de ,arcadores individuales y aquellos que comprenden un juego marcador, es posible determinar si un agente terapeutico o combinacion de agentes ayudara a reducir el indice de crecimiento de tumores en un medio clinico.
MXPA05005923A 2002-12-06 2003-12-04 Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma. MXPA05005923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43151402P 2002-12-06 2002-12-06
PCT/US2003/038539 WO2004053066A2 (en) 2002-12-06 2003-12-04 Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy

Publications (1)

Publication Number Publication Date
MXPA05005923A true MXPA05005923A (es) 2005-09-21

Family

ID=32507743

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005923A MXPA05005923A (es) 2002-12-06 2003-12-04 Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.

Country Status (9)

Country Link
US (3) US20040156854A1 (es)
EP (1) EP1581629B1 (es)
JP (2) JP5717937B2 (es)
AU (1) AU2003298873B2 (es)
CA (1) CA2508348C (es)
ES (1) ES2542328T3 (es)
HK (1) HK1086027A1 (es)
MX (1) MXPA05005923A (es)
WO (1) WO2004053066A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20090215024A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Biomarkers upregulated in prostate cancer
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US20090215058A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
WO2004052184A2 (en) * 2002-12-12 2004-06-24 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
CA2558014A1 (en) * 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
CA3002661C (en) 2004-05-21 2022-03-15 The Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
WO2006053328A2 (en) * 2004-11-12 2006-05-18 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring prostate disease
WO2006101535A1 (en) * 2005-03-23 2006-09-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of proteasome function to potentiate the proapoptotic and antitumor activity of cytokines
JP4887505B2 (ja) * 2005-04-18 2012-02-29 国立大学法人浜松医科大学 癌の転移性及び浸潤能の検査方法
WO2006133420A2 (en) * 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
US20090017006A1 (en) * 2005-07-06 2009-01-15 Biodevelops Pharma Entwicklung Gmbh Use of a compound for enhancing the expression of membrane proteins on the cell surface
WO2007022041A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Mutations and polymorphisms of hdac3
JP2009509171A (ja) * 2005-09-21 2009-03-05 シーシーシー ダイアグノスティックス， エルエルシー 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
US7894650B2 (en) * 2005-11-10 2011-02-22 Microsoft Corporation Discover biological features using composite images
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
CN100372568C (zh) * 2005-12-09 2008-03-05 中国科学院广州生物医药与健康研究院 化合物mg-132在制备治疗白血病药物中的应用
US7875274B2 (en) * 2005-12-16 2011-01-25 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
JP2009530388A (ja) * 2006-03-20 2009-08-27 エントレメッド インコーポレイテッド ２−メトキシエストラジオールの疾患修飾性抗関節炎活性
EP2021502A4 (en) * 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
WO2008021183A2 (en) * 2006-08-10 2008-02-21 Millennium Pharmaceuticals, Inc. For the identification, assessment, and treatment of patients with cancer therapy
JP2010509221A (ja) * 2006-11-03 2010-03-25 ユニバーシテイ・オブ・メリーランド，ボルテイモア 多発性骨髄腫を治療するためにｓａｈａおよびボルテゾミブを使用する方法
JP5413818B2 (ja) * 2007-03-29 2014-02-12 国立大学法人佐賀大学 蛍光多重染色による蛋白定量法
EP2155231B1 (en) * 2007-04-10 2012-08-08 The Johns Hopkins University Imaging and therapy of virus-associated tumors
US20080317768A1 (en) * 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
CN110372795A (zh) 2007-08-02 2019-10-25 吉利德生物制剂公司 Lox和loxl2抑制剂及其应用
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US7816084B2 (en) 2007-11-30 2010-10-19 Applied Genomics, Inc. TLE3 as a marker for chemotherapy
US20090177450A1 (en) * 2007-12-12 2009-07-09 Lawrence Berkeley National Laboratory Systems and methods for predicting response of biological samples
US20100086922A1 (en) * 2008-05-30 2010-04-08 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
US8321144B2 (en) * 2008-10-23 2012-11-27 Microsoft Corporation Non-contiguous regions processing
EP2342355A4 (en) * 2008-10-29 2012-06-27 Beaumont Hospital William METHODS OF USING BIOMARKERS
CA2748759A1 (en) * 2009-01-02 2010-07-08 The Board Of Trustees Of The University Of Arkansas Uses of bortezomib in predicting survival in multiple myeloma patients
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US20110207144A1 (en) * 2009-08-21 2011-08-25 Derek Marshall In vitro screening assays
BR112012008084A2 (pt) * 2009-08-21 2019-09-24 Gilead Biologics Inc método terapêuticos e composições.
NZ625850A (en) * 2009-08-21 2015-12-24 Gilead Biologics Inc Methods and compositions for treatment of pulmonary fibrotic disorders
MX2012002272A (es) * 2009-08-21 2012-07-03 Gilead Biologics Inc Dominios cataliticos de lisil oxidasa y loxl2.
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
US8853147B2 (en) * 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
WO2011094806A1 (en) * 2010-02-03 2011-08-11 Monash University Diagnostic and prognostic assay for breast cancer
AU2011212830B2 (en) 2010-02-04 2014-05-22 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
JP5740880B2 (ja) 2010-09-15 2015-07-01 株式会社リコー 画像形成装置、及びプログラム
EP2742356B1 (en) 2011-08-11 2016-04-27 Janssen Pharmaceutica N.V. Predictors for cancer treatment
EP2776586B1 (en) * 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2014078571A1 (en) * 2012-11-14 2014-05-22 The Board Of Trustees Of The University Of Arkansas Methods of detecting 14q32 translocations
CA2912312C (en) 2013-05-20 2023-01-24 Board Of Trustees Of The University Of Arkansas Gep5 model for multiple myeloma
EP3594359B1 (en) 2013-11-06 2022-05-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Method for subtyping lymphoma types by means of expression profiling
EP3146067A1 (en) * 2014-05-20 2017-03-29 Erasmus University Medical Center Rotterdam Method for the treatment of multiple myeloma
US10607152B2 (en) * 2015-05-26 2020-03-31 Textio, Inc. Using machine learning to predict outcomes for documents
US20170159130A1 (en) * 2015-12-03 2017-06-08 Amit Kumar Mitra Transcriptional classification and prediction of drug response (t-cap dr)
CN108290622B (zh) 2015-12-30 2020-07-17 现代重工业株式会社 液化气体运输船
CA3021569A1 (en) 2016-04-20 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Evaluation of mantle cell lymphoma and methods related thereto
CN106928370B (zh) * 2016-09-26 2021-02-02 华东师范大学 一种REGγ-20S蛋白酶体抑制剂的筛选系统及其应用
KR102007664B1 (ko) * 2017-07-17 2019-08-07 김준 암 진단기 및 이를 이용한 암 진단시스템
US11804298B2 (en) 2017-07-17 2023-10-31 Joon Kim Cancer diagnostic apparatus and cancer diagnostic system using the same
US11899022B2 (en) 2017-08-23 2024-02-13 The General Hospital Corporation Multiplexed proteomics and predictive drug candidate assessment
EP3502279A1 (en) * 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
WO2019142136A1 (en) * 2018-01-17 2019-07-25 Ods Medical Inc. System and methods for real-time raman spectroscopy for cancer detection
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL97428A0 (en) 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
WO2001002567A1 (en) * 1999-07-02 2001-01-11 Millennium Pharmaceuticals, Inc. 16405 receptor, a g-protein coupled receptor
AU2001239941A1 (en) * 2000-02-29 2001-09-12 The General Hospital Corporation Beta netrin and uses thereof
US20040006205A1 (en) * 2001-04-03 2004-01-08 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
EP1392361A4 (en) * 2001-05-11 2009-08-05 Univ Texas THERAPY BASED ON ANTI-CD26 MONOCLONAL ANTIBODIES AGAINST DISORDERS ASSOCIATED WITH CELLS EXPRESSING CD26
WO2006133420A2 (en) * 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
US20040156854A1 (en) 2004-08-12
JP2010207230A (ja) 2010-09-24
JP2006517093A (ja) 2006-07-20
CA2508348A1 (en) 2004-06-24
AU2003298873A1 (en) 2004-06-30
US20170023577A1 (en) 2017-01-26
WO2004053066A3 (en) 2006-09-08
CA2508348C (en) 2016-07-12
AU2003298873B2 (en) 2011-09-01
WO2004053066A2 (en) 2004-06-24
EP1581629A4 (en) 2007-05-16
JP5896593B2 (ja) 2016-03-30
EP1581629B1 (en) 2015-04-01
ES2542328T3 (es) 2015-08-04
HK1086027A1 (en) 2006-09-08
EP1581629A2 (en) 2005-10-05
JP5717937B2 (ja) 2015-05-13
US20090181393A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
MXPA05005923A (es) Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
WO2006133420A3 (en) Treatment of patients with cancer therapy
WO2008021183A3 (en) For the identification, assessment, and treatment of patients with cancer therapy
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
WO2005120407A3 (en) Preparation for localized delivery of therapeutic agent
MX2010005081A (es) Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco.
WO2002049501A3 (en) Local regional chemotherapy and radiotherapy using in situ hydrogel
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
Tree et al. Prostate stereotactic body radiotherapy—first UK experience
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
EP1426054A4 (en) MEDICAL USE OF A HISTON DEACETYLASE HEMMER AND METHOD FOR ASSESSING ITS ANTITUMOROUS EFFECT
HUP0104669A2 (hu) Sugárkezelés és COX-2 gátló kombinációs terápia daganatok kezelésére
HK1070921A1 (en) Method for determining the expression level of glutathione-s-transferase pi
MXPA04004072A (es) Metodos para valorar y tratar leucemia.
BRPI0503418A (pt) prognóstico para malignidade hematológica
HK1124918A1 (zh) +- 宫頸非典型增生和宫頸癌中的 +、 +腺苷三磷酸酶表達
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
TW200610555A (en) Extended treatment of tumors through vessel occlusion with light activated drugs
TW200724158A (en) Combination therapy in the treatment of cancer
MX2007003272A (es) Tratamiento de la osteoporosis inducida por medio de la falta de androgenos.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
EP1502962A3 (en) Methods for assessing and treating cancer
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition

Legal Events

Date Code Title Description
FG Grant or registration